Lipoprotein(a)

Last updated
LPA
Protein LPA PDB 1i71.png
Available structures
PDB Human UniProt search: PDBe RCSB
Identifiers
Aliases LPA , AK38, APOA, LP, Lipoprotein(a), Lp(a)
External IDs HomoloGene: 87856; GeneCards: LPA; OMA:LPA - orthologs
Orthologs
SpeciesHumanMouse
Entrez

4018

n/a

Ensembl

ENSG00000198670

n/a

UniProt

P08519

n/a

RefSeq (mRNA)

NM_005577

n/a

RefSeq (protein)

n/a

n/a

Location (UCSC) Chr 6: 160.53 – 160.66 Mb n/a
PubMed search [2] n/a
Wikidata
View/Edit Human

Lipoprotein(a) is a low-density lipoprotein variant containing a protein called apolipoprotein(a). Genetic and epidemiological studies have identified lipoprotein(a) as a risk factor for atherosclerosis and related diseases, such as coronary heart disease and stroke. [3] [4] [5] [6]

Lipoprotein(a) was discovered in 1963 by Kåre Berg. [7] The human gene encoding apolipoprotein(a) was successfully cloned in 1987. [8]

Structure

Lipoprotein(a) [Lp(a)] consists of an LDL-like particle and the specific apolipoprotein(a), which is bound covalently to the apoB contained in the outer shell of the particle. Lp(a) plasma concentrations are highly heritable [9] [10] and mainly controlled by the LPA gene [11] located on chromosome 6q25.3–q26. [12] Apo(a) proteins vary in size due to a size polymorphism [KIV-2 VNTR], which is caused by a variable number of kringle IV repeats in the LPA gene. [13] This size variation at the gene level is expressed on the protein level as well, resulting in apo(a) proteins with 10 to more than 50 kringle IV repeats (each of the variable kringle IV consists of 114 amino acids). [8] [14] These variable apo(a) sizes are known as "apo(a) isoforms".

There is a general inverse correlation between the size of the apo(a) isoform and the Lp(a) plasma concentration. [15] One theory explaining this correlation involves different rates of protein synthesis. Specifically, the larger the isoform, the more apo(a) precursor protein accumulates intracellularly in the endoplasmic reticulum. Lp(a) is not fully synthesised until the precursor protein is released from the cell, so the slower rate of production for the larger isoforms limits the plasma concentration. [16] [17]

Populations

Lp(a) concentrations can vary by more than one thousand between individuals, from <0.2 to >200 mg/dL. This range of concentrations is observed in all populations studied by scientists so far. The mean and median concentrations differ among world populations. Most prominently, there is a two- to threefold higher mean Lp(a) plasma concentration in populations of African descent compared to Asian, Oceanic, or European populations. [18] [19] The general inverse correlation between apo(a) isoform size and Lp(a) plasma concentration is observed in all populations. [15] However, it was also discovered that mean Lp(a) associated with certain apo(a) isoforms varies between populations.

In addition to size effects, mutations in the LPA promoter may lead to a decreased apo(a) production. [20]

The Atherosclerosis Risk in Communities (ARIC) Study is a community-based cohort from 4 geographically diverse US communities. The ARIC Study found that the proportion of Atherosclerotic Cardiovascular Disease cases potentially attributable to elevated Lp(a) was 10.2% among Black adults compared with 4.7% among white adults. The population-attributable fraction ratio for Black adults compared with white adults was 2.30. Because the hazard ratios for ASCVD associated with higher Lp(a) did not significantly differ between races, the ARIC study concluded that these differences appeared to be driven largely by racial differences in the distribution of Lp(a) levels. [21]

Function and pathology

Lp(a) is assembled at the hepatocyte cell membrane surface, which is similar to typical LDL particles. However, there are other possible locations of assembly. The particles mainly exist in plasma. [22] [23] [24] [25]

Lp(a) contributes to the process of atherogenesis. The structure of apolipoprotein(a) is similar to plasminogen and tPA (tissue plasminogen activator) and it competes with plasminogen for its binding site, leading to reduced fibrinolysis. [26] [27] Also, because Lp(a) stimulates secretion of PAI-1, it leads to thrombogenesis. [28] [29] [30] It also may enhance coagulation by inhibiting the function of tissue factor pathway inhibitor. [31]

Moreover, Lp(a) carries atherosclerosis-causing cholesterol and binds atherogenic pro-inflammatory oxidised phospholipids as a preferential carrier of oxidised phospholipids in human plasma, [32] which attracts inflammatory cells to vessel walls and leads to smooth muscle cell proliferation. [33] [34] [35] Moreover, Lp(a) also is hypothesised to be involved in wound healing and tissue repair by interacting with components of the vascular wall and extracellular matrix. [36] [37] Apo(a), a distinct feature of the Lp(a) particle, binds to immobilized fibronectin and endows Lp(a) with the serine-proteinase-type proteolytic activity. [38]

Nonetheless, individuals without Lp(a) or with very low Lp(a) levels seem to be healthy.[ citation needed ] Thus, plasma Lp(a) is not vital, at least under normal environmental conditions.[ citation needed ] Since apo(a)/Lp(a) appeared rather recently in mammalian evolution – only old world monkeys and humans have been shown to harbour Lp(a) – its function might not be vital, but just evolutionarily advantageous under certain environmental conditions, e.g. in case of exposure to certain infectious diseases. [20]

Another possibility, suggested by Linus Pauling, is that Lp(a) is a primate adaptation to L-gulonolactone oxidase (GULO) deficiency, found only in certain lines of mammals. GULO is required for converting glucose to ascorbic acid (vitamin C), which is needed to repair arteries; following the loss of GULO, those primates who adopted diets less abundant in vitamin C may have used Lp(a) as an ascorbic-acid surrogate to repair arterial walls. [39]

Catabolism and clearance

The half-life of Lp(a) in circulation is approximately three to four days. [23] The mechanism and sites of Lp(a) catabolism are largely unknown. The LDL receptor has been reported as a receptor for Lp(a) clearance, but is not a major pathway of Lp(a) metabolism under normal or hypercholesterolemic conditions. [40] [41] [42] The kidney has been identified as playing a role in Lp(a) clearance from plasma. [43]

Disease

High Lp(a) in blood correlates with coronary heart disease (CHD), cardiovascular disease (CVD), atherosclerosis, thrombosis, and stroke. [44] However, the association between Lp(a) levels and stroke is not as strong as that between Lp(a) and cardiovascular disease. [3] Lp(a) concentrations may be affected by disease states (for example kidney failure), but are only slightly affected by diet, exercise, and other environmental factors.

Most commonly prescribed lipid-reducing drugs have little or no effect on Lp(a) concentration. Results using statin medications have been mixed in most trials, although a meta-analysis published in 2012 suggests that atorvastatin may be of benefit. [45]

Niacin (Vitamin B3) has been shown to reduce the levels of Lp(a) significantly in individuals with high levels of low-molecular weight Lp(a). [46] [47]

High Lp(a) correlates with early atherosclerosis independently of other cardiac risk factors, including LDL. In patients with advanced cardiovascular disease, Lp(a) indicates a coagulant risk of plaque thrombosis. Apo(a) contains domains that are very similar to plasminogen (PLG). Lp(a) accumulates in the vessel wall and inhibits the binding of PLG to the cell surface, reducing plasmin generation, which increases clotting. This inhibition of PLG by Lp(a) also promotes the proliferation of smooth muscle cells. These unique features of Lp(a) suggest that Lp(a) causes generation of clots and atherosclerosis. [48]

In one homogeneous tribal population of Tanzania, vegetarians have higher levels of Lp(a) than fish eaters, raising the possibility that pharmacologic amounts of fish oil supplements may help lower the levels of Lp(a). [49] Researchers in studies in 1995 and 1998 concluded that regular consumption of moderate amounts of alcohol led to a significant decline in plasma levels of Lp(a). [50] Other studies did not report this.

Diagnostic testing

Numerous studies confirming a strong correlation between elevated Lp(a) and heart disease have led to the consensus that Lp(a) is an important independent predictor of cardiovascular disease. [3] Animal studies have shown that Lp(a) may directly contribute to atherosclerotic damage by increasing plaque size, inflammation, instability, and smooth muscle cell growth. [51] Genetic data also support the theory that Lp(a) causes cardiovascular disease. [4]

The European Atherosclerosis Society currently recommends that patients with a moderate or high risk of cardiovascular disease should have their Lp(a) levels checked. Any patient with one of the following risk factors should be screened:

If the level is elevated, treatment should be initiated to bring the level below 50 mg/dL. In addition, the patient's other cardiovascular risk factors (including LDL levels) should be managed optimally. [3] Apart from the total Lp(a) plasma concentration, the apo(a) isoform might be an important risk parameter as well. [52] [53]

Prior studies of the relationship between Lp(a) and ethnicity have shown inconsistent results. Lp(a) levels seem to differ in different populations. For example, in some African populations, Lp(a) levels are higher on average than in other groups, so that using a risk threshold of 30 mg/dl could classify over 50% of the individuals as higher risk. [54] [55] [56] [57] Some part of this complexity may be related to the different genetic factors involved in determining Lp(a) levels. One recent study showed that in different ethnic groups, different genetic alterations were associated with increased Lp(a) levels. [58]

More recent data suggest that prior studies were underpowered. The Atherosclerosis Risk in Communities (ARIC) Study followed 3467 African Americans and 9851 whites for 20 years. The researchers found that an elevated Lp(a) conferred the same risk in each group. African Americans had roughly three times the level of Lp(a), however, and Lp(a) also predicted an increased risk of stroke. [59]

Approximate levels of risk are indicated by the results below, although at present there are a variety of different methods by which to measure Lp(a). A standardized international reference material has been developed and is accepted by the WHO Expert Committee on Biological Standardization and the International Federation of Clinical Chemistry and Laboratory Medicine. Although further standardization is still needed, development of a reference material is an importance step toward standardizing results. [60] [61]

Lipoprotein(a) - Lp(a) [62]

Desirable: <14 mg/dL (<35 nmol/L)
Borderline risk: 14–30 mg/dL (35–75 nmol/L)
High risk: 31–50 mg/dL (75–125 nmol/L)
Very high risk: >50 mg/dL (>125 nmol/L)

Lp(a) appears with different isoforms (per kringle repeats) of apolipoprotein; 40% of the variation in Lp(a) levels when measured in mg/dl can be attributed to different isoforms. Lighter Lp(a) are also associated with disease. Thus, a test with simple quantitative results may not provide a complete assessment of risk. [63]

The US FDA has given the Tina-quant® lipoprotein Lp(a) RxDx assay from Roche, a Breakthrough Device Designation. The assay is designed to identify patients who may benefit from therapies aimed at decreasing Lp(a) levels. [64]

Treatment

The current simplest treatment for elevated Lp(a) is to take 1–3 grams of niacin daily, typically in an extended-release form. Niacin therapy may reduce Lp(a) levels by 20–30%. [65]

A meta-analysis suggested that atorvastatin may lower Lp(a) levels. [45] In severe cases, such as familial hypercholesterolemia or treatment-resistant hypercholesterolemia, LDL apheresis may dramatically reduce Lp(a). The goal of the treatment is to reduce levels to below 50 mg/dL. Cost is prohibitively high. [3]

A meta-analysis of six clinical trials confirmed that flaxseed supplementation modestly lowers Lp(a) levels. [66]

Testosterone is known to reduce Lp(a) levels. [67] Testosterone replacement therapy also appears to be associated with lower Lp(a) levels. [68] [69] Estrogen replacement therapy in post-menopausal women will reduce Lp(a). [70] Raloxifene has not been shown to reduce Lp(a), while tamoxifen has. [71]

L-carnitine may also reduce Lp(a) levels. A systematic review and meta-analysis found a significant reduction with oral but not intravenous carnitine. [72] Other medications that are in various stages of development include thyromimetics, cholesterol-ester-transfer protein (CETP inhibitors), anti-sense oligonucleopeptides (such as Pelacarsen and Olpasiran), and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. [73] [74]

The American Academy of Pediatrics now recommends that all children between the ages of nine and eleven years old be screened for hyperlipidemia. Lp(a) levels should be considered in particular in children with a family history of early heart disease or high blood cholesterol levels. However, there have not been enough studies to determine which therapies might be beneficial. [75]

Interactions

Lp(a) has been shown to interact with calnexin, [76] [77] fibronectin, [38] and fibrinogen beta chain. [78]

See also

Related Research Articles

<span class="mw-page-title-main">Cholesterol</span> Sterol biosynthesized by all animal cells

Cholesterol is the principal sterol of all higher animals, distributed in body tissues, especially the brain and spinal cord, and in animal fats and oils.

High-density lipoprotein (HDL) is one of the five major groups of lipoproteins. Lipoproteins are complex particles composed of multiple proteins which transport all fat molecules (lipids) around the body within the water outside cells. They are typically composed of 80–100 proteins per particle. HDL particles enlarge while circulating in the blood, aggregating more fat molecules and transporting up to hundreds of fat molecules per particle.

<span class="mw-page-title-main">Low-density lipoprotein</span> One of the five major groups of lipoprotein

Low-density lipoprotein (LDL) is one of the five major groups of lipoprotein that transport all fat molecules around the body in extracellular water. These groups, from least dense to most dense, are chylomicrons, very low-density lipoprotein (VLDL), intermediate-density lipoprotein (IDL), low-density lipoprotein (LDL) and high-density lipoprotein (HDL). LDL delivers fat molecules to cells. LDL has been associated with the progression of atherosclerosis.

<span class="mw-page-title-main">Lipoprotein</span> Biochemical assembly whose purpose is to transport hydrophobic lipid molecules

A lipoprotein is a biochemical assembly whose primary function is to transport hydrophobic lipid molecules in water, as in blood plasma or other extracellular fluids. They consist of a triglyceride and cholesterol center, surrounded by a phospholipid outer shell, with the hydrophilic portions oriented outward toward the surrounding water and lipophilic portions oriented inward toward the lipid center. A special kind of protein, called apolipoprotein, is embedded in the outer shell, both stabilising the complex and giving it a functional identity that determines its role.

<span class="mw-page-title-main">Chylomicron</span> One of the five major groups of lipoprotein

Chylomicrons, also known as ultra low-density lipoproteins (ULDL), are lipoprotein particles that consist of triglycerides (85–92%), phospholipids (6–12%), cholesterol (1–3%), and proteins (1–2%). They transport dietary lipids, such as fats and cholesterol, from the intestines to other locations in the body, within the water-based solution of the bloodstream. ULDLs are one of the five major groups lipoproteins are divided into based on their density. A protein specific to chylomicrons is ApoB48.

<span class="mw-page-title-main">Apolipoprotein</span> Proteins that bind lipids to transport them in body fluids

Apolipoproteins are proteins that bind lipids to form lipoproteins. They transport lipids in blood, cerebrospinal fluid and lymph.

Hyperlipidemia is abnormally high levels of any or all lipids or lipoproteins in the blood. The term hyperlipidemia refers to the laboratory finding itself and is also used as an umbrella term covering any of various acquired or genetic disorders that result in that finding. Hyperlipidemia represents a subset of dyslipidemia and a superset of hypercholesterolemia. Hyperlipidemia is usually chronic and requires ongoing medication to control blood lipid levels.

<span class="mw-page-title-main">LDL receptor</span> Mammalian protein found in Homo sapiens

The low-density lipoprotein receptor (LDL-R) is a mosaic protein of 839 amino acids that mediates the endocytosis of cholesterol-rich low-density lipoprotein (LDL). It is a cell-surface receptor that recognizes apolipoprotein B100 (ApoB100), which is embedded in the outer phospholipid layer of very low-density lipoprotein (VLDL), their remnants—i.e. intermediate-density lipoprotein (IDL), and LDL particles. The receptor also recognizes apolipoprotein E (ApoE) which is found in chylomicron remnants and IDL. In humans, the LDL receptor protein is encoded by the LDLR gene on chromosome 19. It belongs to the low density lipoprotein receptor gene family. It is most significantly expressed in bronchial epithelial cells and adrenal gland and cortex tissue.

<span class="mw-page-title-main">Campesterol</span> Chemical compound

Campesterol is a phytosterol whose chemical structure is similar to that of cholesterol, and is one of the ingredients for E number E499.

<span class="mw-page-title-main">Apolipoprotein E</span> Cholesterol-transporting protein most notably implicated in Alzheimers disease

Apolipoprotein E (Apo-E) is a protein involved in the metabolism of fats in the body of mammals. A subtype is implicated in Alzheimer's disease and cardiovascular diseases. It is encoded in humans by the gene APOE.

<span class="mw-page-title-main">Apolipoprotein B</span> Protein-coding gene in the species Homo sapiens

Apolipoprotein B (ApoB) is a protein that in humans is encoded by the APOB gene. It is commonly used to detect risk of atherosclerotic cardiovascular disease.

<span class="mw-page-title-main">Apolipoprotein C-II</span> Protein-coding gene in the species Homo sapiens

Apolipoprotein C-II, or apolipoprotein C2 is a protein that in humans is encoded by the APOC2 gene.

<span class="mw-page-title-main">Familial hypercholesterolemia</span> Genetic disorder characterized by high cholesterol levels

Familial hypercholesterolemia (FH) is a genetic disorder characterized by high cholesterol levels, specifically very high levels of low-density lipoprotein cholesterol, in the blood and early cardiovascular diseases. The most common mutations diminish the number of functional LDL receptors in the liver or produce abnormal LDL receptors that never go to the cell surface to function properly. Since the underlying body biochemistry is slightly different in individuals with FH, their high cholesterol levels are less responsive to the kinds of cholesterol control methods which are usually more effective in people without FH. Nevertheless, treatment is usually effective.

<span class="mw-page-title-main">Apolipoprotein AI</span> Protein used in lipid metabolism

Apolipoprotein AI(Apo-AI) is a protein that in humans is encoded by the APOA1 gene. As the major component of HDL particles, it has a specific role in lipid metabolism.

<span class="mw-page-title-main">Apolipoprotein C-III</span> Protein-coding gene in the species Homo sapiens

Apolipoprotein C-III also known as apo-CIII, and apolipoprotein C3, is a protein that in humans is encoded by the APOC3 gene. Apo-CIII is secreted by the liver as well as the small intestine, and is found on triglyceride-rich lipoproteins such as chylomicrons, very low density lipoprotein (VLDL), and remnant cholesterol.

<span class="mw-page-title-main">Apolipoprotein C-IV</span> Protein-coding gene in the species Homo sapiens

Apolipoprotein C-IV, also known as apolipoprotein C4, is a protein that in humans is encoded by the APOC4 gene.

<span class="mw-page-title-main">APOA5</span> Protein-coding gene in the species Homo sapiens

Apolipoprotein A-V is a protein that in humans is encoded by the APOA5 gene on chromosome 11. It is significantly expressed in liver. The protein encoded by this gene is an apolipoprotein and an important determinant of plasma triglyceride levels, a major risk factor for coronary artery disease. It is a component of several lipoprotein fractions including VLDL, HDL, chylomicrons. It is believed that apoA-V affects lipoprotein metabolism by interacting with LDL-R gene family receptors. Considering its association with lipoprotein levels, APOA5 is implicated in metabolic syndrome. The APOA5 gene also contains one of 27 SNPs associated with increased risk of coronary artery disease.

<span class="mw-page-title-main">LRP1</span> Mammalian protein found in Homo sapiens

Low density lipoprotein receptor-related protein 1 (LRP1), also known as alpha-2-macroglobulin receptor (A2MR), apolipoprotein E receptor (APOER) or cluster of differentiation 91 (CD91), is a protein forming a receptor found in the plasma membrane of cells involved in receptor-mediated endocytosis. In humans, the LRP1 protein is encoded by the LRP1 gene. LRP1 is also a key signalling protein and, thus, involved in various biological processes, such as lipoprotein metabolism and cell motility, and diseases, such as neurodegenerative diseases, atherosclerosis, and cancer.

<span class="mw-page-title-main">PCSK9</span> Mammalian protein found in humans

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is an enzyme encoded by the PCSK9 gene in humans on chromosome 1. It is the 9th member of the proprotein convertase family of proteins that activate other proteins. Similar genes (orthologs) are found across many species. As with many proteins, PCSK9 is inactive when first synthesized, because a section of peptide chains blocks their activity; proprotein convertases remove that section to activate the enzyme. The PCSK9 gene also contains one of 27 loci associated with increased risk of coronary artery disease.

<span class="mw-page-title-main">Lipoprotein-associated phospholipase A2</span> Protein-coding gene in the species Homo sapiens

Lipoprotein-associated phospholipase A2 (Lp-PLA2) also known as platelet-activating factor acetylhydrolase (PAF-AH) is a phospholipase A2 enzyme that in humans is encoded by the PLA2G7 gene. Lp-PLA2 is a 45-kDa protein of 441 amino acids. It is one of several PAF acetylhydrolases.

References

  1. 1 2 3 GRCh38: Ensembl release 89: ENSG00000198670 – Ensembl, May 2017
  2. ↑ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  3. 1 2 3 4 5 6 Nordestgaard BG, Chapman MJ, Ray K, Borén J, Andreotti F, Watts GF, et al. (December 2010). "Lipoprotein(a) as a cardiovascular risk factor: current status". European Heart Journal. 31 (23): 2844–2853. doi:10.1093/eurheartj/ehq386. PMC   3295201 . PMID   20965889.{{cite journal}}: CS1 maint: overridden setting (link)
  4. 1 2 Kamstrup PR, Tybjærg-Hansen A, Nordestgaard BG (April 2011). "Lipoprotein(a) and risk of myocardial infarction--genetic epidemiologic evidence of causality". Scandinavian Journal of Clinical and Laboratory Investigation. 71 (2): 87–93. doi:10.3109/00365513.2010.550311. PMID   21231777. S2CID   23045050.
  5. ↑ Smolders B, Lemmens R, Thijs V (June 2007). "Lipoprotein (a) and stroke: a meta-analysis of observational studies". Stroke. 38 (6): 1959–1966. doi: 10.1161/STROKEAHA.106.480657 . PMID   17478739.
  6. ↑ Amiri M, Raeisi-Dehkordi H, Verkaar AJ, Wu Y, van Westing AC, Berk KA, et al. (May 2023). "Circulating lipoprotein (a) and all-cause and cause-specific mortality: a systematic review and dose-response meta-analysis". European Journal of Epidemiology. 38 (5): 485–499. doi: 10.1007/s10654-022-00956-4 . PMC   10164031 . PMID   36708412.{{cite journal}}: CS1 maint: overridden setting (link)
  7. ↑ Berg K (1963). "A new serum type system in man—the Ld system". Acta Pathologica et Microbiologica Scandinavica. 59 (3): 369–382. doi:10.1111/j.1699-0463.1963.tb01808.x. PMID   14064818.
  8. 1 2 McLean JW, Tomlinson JE, Kuang WJ, Eaton DL, Chen EY, Fless GM, et al. (1987). "cDNA sequence of human apolipoprotein(a) is homologous to plasminogen". Nature. 330 (6144): 132–137. Bibcode:1987Natur.330..132M. doi:10.1038/330132a0. PMID   3670400. S2CID   4344313.{{cite journal}}: CS1 maint: overridden setting (link)
  9. ↑ Wade DP, Puckey LH, Knight BL, Acquati F, Mihalich A, Taramelli R (November 1997). "Characterization of multiple enhancer regions upstream of the apolipoprotein(a) gene". The Journal of Biological Chemistry. 272 (48): 30387–30399. doi: 10.1074/jbc.272.48.30387 . PMID   9374529.
  10. ↑ Langsted A, Nordestgaard BG (April 2022). "Value of Genetic Testing for Lipoprotein(a) Variants". Circulation. Genomic and Precision Medicine. 15 (2): e003737. doi: 10.1161/CIRCGEN.122.003737 . PMID   35311528.
  11. ↑ Coassin S, Chemello K, Khantalin I, Forer L, Döttelmayer P, Schönherr S, et al. (April 2022). "Genome-Wide Characterization of a Highly Penetrant Form of Hyperlipoprotein(a)emia Associated With Genetically Elevated Cardiovascular Risk". Circulation. Genomic and Precision Medicine. 15 (2): e003489. doi: 10.1161/CIRCGEN.121.003489 . PMC   9018215 . PMID   35133173.{{cite journal}}: CS1 maint: overridden setting (link)
  12. ↑ "Symbol report for LPA". HGNC. Hugo Gene Nomenclature Committee. Retrieved 19 June 2024.
  13. ↑ Scipione CA, Koschinsky ML, Boffa MB (2018-01-02). "Lipoprotein(a) in clinical practice: New perspectives from basic and translational science". Critical Reviews in Clinical Laboratory Sciences. 55 (1): 33–54. doi:10.1080/10408363.2017.1415866. ISSN   1040-8363. PMID   29262744.
  14. ↑ Utermann G, Menzel HJ, Kraft HG, Duba HC, Kemmler HG, Seitz C (August 1987). "Lp(a) glycoprotein phenotypes. Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma". The Journal of Clinical Investigation. 80 (2): 458–465. doi:10.1172/JCI113093. PMC   442258 . PMID   2956279.
  15. 1 2 Sandholzer C, Hallman DM, Saha N, Sigurdsson G, Lackner C, Császár A, et al. (April 1991). "Effects of the apolipoprotein(a) size polymorphism on the lipoprotein(a) concentration in 7 ethnic groups". Human Genetics. 86 (6): 607–614. doi:10.1007/BF00201550. PMID   2026424. S2CID   19657929.{{cite journal}}: CS1 maint: overridden setting (link)
  16. ↑ Lobentanz EM, Krasznai K, Gruber A, Brunner C, Müller HJ, Sattler J, et al. (April 1998). "Intracellular metabolism of human apolipoprotein(a) in stably transfected Hep G2 cells". Biochemistry. 37 (16): 5417–5425. doi:10.1021/bi972761t. PMID   9548923.{{cite journal}}: CS1 maint: overridden setting (link)
  17. ↑ Brunner C, Lobentanz EM, Pethö-Schramm A, Ernst A, Kang C, Dieplinger H, et al. (December 1996). "The number of identical kringle IV repeats in apolipoprotein(a) affects its processing and secretion by HepG2 cells". The Journal of Biological Chemistry. 271 (50): 32403–32410. doi: 10.1074/jbc.271.50.32403 . PMID   8943305.{{cite journal}}: CS1 maint: overridden setting (link)
  18. ↑ Patel AP, Wang (汪敏先) M, Pirruccello JP, Ellinor PT, Ng K, Kathiresan S, Khera AV. Lp(a) (Lipoprotein[a]) Concentrations and Incident Atherosclerotic Cardiovascular Disease: New Insights From a Large National Biobank. Arterioscler Thromb Vasc Biol. 2021 Jan;41(1):465-474. doi: 10.1161/ATVBAHA.120.315291. Epub 2020 Oct 29. PMID: 33115266; PMCID: PMC7769893.
  19. ↑ Kronenberg F, Mora S, Stroes ESG, Ference BA, Arsenault BJ, Berglund L, Dweck MR, Koschinsky M, Lambert G, Mach F, McNeal CJ, Moriarty PM, Natarajan P, Nordestgaard BG, Parhofer KG, Virani SS, von Eckardstein A, Watts GF, Stock JK, Ray KK, Tokgözoğlu LS, Catapano AL. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022 Oct 14;43(39):3925-3946. doi: 10.1093/eurheartj/ehac361. PMID: 36036785; PMCID: PMC9639807.
  20. 1 2 Pati N, Rouf A, Pati U (February 2000). "Simultaneous mutations (A/G(-418) and C/T(-384)) in the apo(a) promoter of individuals with low Lp(a) levels". Molecular Genetics and Metabolism. 69 (2): 165–167. doi:10.1006/mgme.1999.2956. PMID   10720444.
  21. ↑ Grant JK, Martin SS, Zhang S, Matsushita K, Virani SS, Blumenthal RS, Hoogeveen RC, Boerwinkle E, Ballantyne CM, Coresh J, Ndumele CE. Racial Differences in the Burden of Atherosclerotic Cardiovascular Disease Related to Elevated Lipoprotein(a) Levels: The ARIC Study. Circulation. 2024 Jul 16;150(3):250-252. doi: 10.1161/CIRCULATIONAHA.124.069582. Epub 2024 Jul 15. PMID: 39008561.
  22. ↑ White AL, Lanford RE (November 1994). "Cell surface assembly of lipoprotein(a) in primary cultures of baboon hepatocytes". The Journal of Biological Chemistry. 269 (46): 28716–28723. doi: 10.1016/S0021-9258(19)61964-2 . PMID   7961823.
  23. 1 2 Rader DJ, Cain W, Zech LA, Usher D, Brewer HB (February 1993). "Variation in lipoprotein(a) concentrations among individuals with the same apolipoprotein (a) isoform is determined by the rate of lipoprotein(a) production". The Journal of Clinical Investigation. 91 (2): 443–447. doi:10.1172/JCI116221. PMC   287951 . PMID   8432853.
  24. ↑ Dieplinger H, Utermann G (June 1999). "The seventh myth of lipoprotein(a): where and how is it assembled?". Current Opinion in Lipidology. 10 (3): 275–283. doi:10.1097/00041433-199906000-00010. PMID   10431664.
  25. ↑ Koschinsky ML, Marcovina SM (April 2004). "Structure-function relationships in apolipoprotein(a): insights into lipoprotein(a) assembly and pathogenicity". Current Opinion in Lipidology. 15 (2): 167–174. doi:10.1097/00041433-200404000-00009. PMID   15017359. S2CID   45103589.
  26. ↑ Romagnuolo R, Scipione CA, Bazzi ZA, Boffa MB, Koschinsky ML (August 2018). "Inhibition of pericellular plasminogen activation by apolipoprotein(a): Roles of urokinase plasminogen activator receptor and integrins αMβ2 and αVβ3". Atherosclerosis. 275: 11–21. doi:10.1016/j.atherosclerosis.2018.05.029. PMID   29852400.
  27. ↑ Romagnuolo R, DeMarco K, Scipione CA, Boffa MB, Koschinsky ML (September 2018). "Apolipoprotein(a) inhibits the conversion of Glu-plasminogen to Lys-plasminogen on the surface of vascular endothelial and smooth muscle cells". Thrombosis Research. 169: 1–7. doi:10.1016/j.thromres.2018.07.002. PMID   29990619.
  28. ↑ Banach M, Aronow WS, Serban C, Sahabkar A, Rysz J, Voroneanu L, et al. (2015). "Lipids, blood pressure and kidney update 2014". Pharmacological Research. 95–96: 111–125. doi:10.1016/j.phrs.2015.03.009. PMC   4696333 . PMID   25819754.
  29. ↑ Nordestgaard BG, Chapman MJ, Ray K, Borén J, Andreotti F, Watts GF, et al. (December 2010). "Lipoprotein(a) as a cardiovascular risk factor: current status". European Heart Journal. 31 (23): 2844–2853. doi:10.1093/eurheartj/ehq386. PMC   3295201 . PMID   20965889.{{cite journal}}: CS1 maint: overridden setting (link)
  30. ↑ Romagnuolo R, Scipione CA, Boffa MB, Marcovina SM, Seidah NG, Koschinsky ML (May 2015). "Lipoprotein(a) catabolism is regulated by proprotein convertase subtilisin/kexin type 9 through the low density lipoprotein receptor". The Journal of Biological Chemistry. 290 (18): 11649–11662. doi: 10.1074/jbc.M114.611988 . PMC   4416867 . PMID   25778403.
  31. ↑ Pan S, Kleppe LS, Witt TA, Mueske CS, Simari RD (September 2004). "The effect of vascular smooth muscle cell-targeted expression of tissue factor pathway inhibitor in a murine model of arterial thrombosis". Thrombosis and Haemostasis. 92 (3): 495–502. doi:10.1160/TH04-01-0006. PMID   15351845. S2CID   1212821.
  32. ↑ Tsimikas S, Brilakis ES, Miller ER, McConnell JP, Lennon RJ, Kornman KS, et al. (July 2005). "Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease". The New England Journal of Medicine. 353 (1): 46–57. doi: 10.1056/NEJMoa043175 . PMID   16000355.{{cite journal}}: CS1 maint: overridden setting (link)
  33. ↑ Banach M (April 2016). "Lipoprotein (a)-We Know So Much Yet Still Have Much to Learn …". Journal of the American Heart Association. 5 (4): e003597. doi:10.1161/JAHA.116.003597. PMC   4859302 . PMID   27108250.
  34. ↑ Gouni-Berthold I, Berthold HK (November 2011). "Lipoprotein(a): current perspectives". Current Vascular Pharmacology. 9 (6): 682–692. doi:10.2174/157016111797484071. PMID   21529331.
  35. ↑ Tsimikas S, Witztum JL (August 2008). "The role of oxidized phospholipids in mediating lipoprotein(a) atherogenicity". Current Opinion in Lipidology. 19 (4): 369–377. doi:10.1097/MOL.0b013e328308b622. PMID   18607184. S2CID   24081304.
  36. ↑ Brown MS, Goldstein JL (1987). "Plasma lipoproteins: teaching old dogmas new tricks". Nature. 330 (6144): 113–114. doi: 10.1038/330113a0 . PMID   3670399. S2CID   4322332.
  37. ↑ Kostner GM, Bihari-Varga M (August 1990). "Is the atherogenicity of Lp(a) caused by its reactivity with proteoglycans?". European Heart Journal. 11 Suppl E (Suppl E): 184–189. doi:10.1093/eurheartj/11.suppl_e.184. PMID   2146124.
  38. 1 2 Salonen EM, Jauhiainen M, Zardi L, Vaheri A, Ehnholm C (December 1989). "Lipoprotein(a) binds to fibronectin and has serine proteinase activity capable of cleaving it". The EMBO Journal. 8 (13): 4035–4040. doi:10.1002/j.1460-2075.1989.tb08586.x. PMC   401578 . PMID   2531657.
  39. ↑ Pauling L, Rath M (1992). "A Unified Theory of Human Cardiovascular Disease" (PDF). Journal of Orthomolecular Medicine. 7 (1). S2CID   37023416. Archived (PDF) from the original on 2018-12-26. Retrieved 2012-01-09.
  40. ↑ Romagnuolo R, Scipione CA, Boffa MB, Marcovina SM, Seidah NG, Koschinsky ML (May 2015). "Lipoprotein(a) catabolism is regulated by proprotein convertase subtilisin/kexin type 9 through the low density lipoprotein receptor". The Journal of Biological Chemistry. 290 (18): 11649–11662. doi: 10.1074/jbc.M114.611988 . PMC   4416867 . PMID   25778403.
  41. ↑ Knight BL, Perombelon YF, Soutar AK, Wade DP, Seed M (April 1991). "Catabolism of lipoprotein(a) in familial hypercholesterolaemic subjects". Atherosclerosis. 87 (2–3): 227–237. doi:10.1016/0021-9150(91)90025-X. PMID   1830206.
  42. ↑ Rader DJ, Mann WA, Cain W, Kraft HG, Usher D, Zech LA, et al. (March 1995). "The low density lipoprotein receptor is not required for normal catabolism of Lp(a) in humans". The Journal of Clinical Investigation. 95 (3): 1403–1408. doi:10.1172/JCI117794. PMC   441483 . PMID   7883987.{{cite journal}}: CS1 maint: overridden setting (link)
  43. ↑ Albers JJ, Koschinsky ML, Marcovina SM (May 2007). "Evidence mounts for a role of the kidney in lipoprotein(a) catabolism". Kidney International. 71 (10): 961–962. doi: 10.1038/sj.ki.5002240 . PMID   17495935.
  44. ↑ Christian Wilde (2003). Hidden Causes of Heart Attack and Stroke: Inflammation, Cardiology's New Frontier. Abigon Press. pp. 182–183. ISBN   978-0-9724959-0-5.
  45. 1 2 Takagi H, Umemoto T (January 2012). "Atorvastatin decreases lipoprotein(a): a meta-analysis of randomized trials". International Journal of Cardiology. 154 (2): 183–186. doi:10.1016/j.ijcard.2011.09.060. PMID   21996415.
  46. ↑ Sahebkar A, Reiner Ž, Simental-Mendía LE, Ferretti G, Cicero AF (November 2016). "Effect of extended-release niacin on plasma lipoprotein(a) levels: A systematic review and meta-analysis of randomized placebo-controlled trials". Metabolism. 65 (11): 1664–1678. doi:10.1016/j.metabol.2016.08.007. PMID   27733255.
  47. ↑ Artemeva NV, Safarova MS, Ezhov MV, Afanasieva OI, Dmitrieva OA, Pokrovsky SN (May 2015). "Lowering of lipoprotein(a) level under niacin treatment is dependent on apolipoprotein(a) phenotype". Atherosclerosis. Supplements. 18: 53–58. doi:10.1016/j.atherosclerosissup.2015.02.008. PMID   25936305.
  48. ↑ Caplice NM, Panetta C, Peterson TE, Kleppe LS, Mueske CS, Kostner GM, et al. (November 2001). "Lipoprotein (a) binds and inactivates tissue factor pathway inhibitor: a novel link between lipoproteins and thrombosis". Blood. 98 (10): 2980–2987. doi: 10.1182/blood.V98.10.2980 . PMID   11698280.{{cite journal}}: CS1 maint: overridden setting (link)
  49. ↑ Marcovina SM, Kennedy H, Bittolo Bon G, Cazzolato G, Galli C, Casiglia E, et al. (May 1999). "Fish intake, independent of apo(a) size, accounts for lower plasma lipoprotein(a) levels in Bantu fishermen of Tanzania: The Lugalawa Study". Arteriosclerosis, Thrombosis, and Vascular Biology. 19 (5): 1250–1256. doi: 10.1161/01.ATV.19.5.1250 . PMID   10323776.{{cite journal}}: CS1 maint: overridden setting (link)
  50. ↑ Sharpe PC, Young IS, Evans AE (May 1998). "Effect of moderate alcohol consumption on lp(a) lipoprotein concentrations. Reduction is supported by other studies". BMJ. 316 (7145): 1675. doi:10.1136/bmj.316.7145.1675. PMC   1113249 . PMID   9603764.
  51. ↑ Kamstrup PR, Nordestgaard BG (October 2009). "Lipoprotein(a) should be taken much more seriously". Biomarkers in Medicine. 3 (5): 439–441. doi: 10.2217/bmm.09.57 . PMID   20477514.
  52. ↑ Klausen IC, Sjøl A, Hansen PS, Gerdes LU, Møller L, Lemming L, et al. (July 1997). "Apolipoprotein(a) isoforms and coronary heart disease in men: a nested case-control study". Atherosclerosis. 132 (1): 77–84. doi:10.1016/S0021-9150(97)00071-3. PMID   9247362.{{cite journal}}: CS1 maint: overridden setting (link)
  53. ↑ Paultre F, Pearson TA, Weil HF, Tuck CH, Myerson M, Rubin J, et al. (December 2000). "High levels of Lp(a) with a small apo(a) isoform are associated with coronary artery disease in African American and white men". Arteriosclerosis, Thrombosis, and Vascular Biology. 20 (12): 2619–2624. doi: 10.1161/01.ATV.20.12.2619 . PMID   11116062. S2CID   12507462.{{cite journal}}: CS1 maint: overridden setting (link)
  54. ↑ Helmhold M, Bigge J, Muche R, Mainoo J, Thiery J, Seidel D, et al. (December 1991). "Contribution of the apo[a] phenotype to plasma Lp[a] concentrations shows considerable ethnic variation". Journal of Lipid Research. 32 (12): 1919–1928. doi: 10.1016/S0022-2275(20)41895-4 . PMID   1840066.
  55. ↑ Cobbaert C, Mulder P, Lindemans J, Kesteloot H (September 1997). "Serum LP(a) levels in African aboriginal Pygmies and Bantus, compared with Caucasian and Asian population samples". Journal of Clinical Epidemiology. 50 (9): 1045–1053. doi:10.1016/S0895-4356(97)00129-7. hdl: 1765/68815 . PMID   9363039. S2CID   2188933. Archived from the original on 2024-06-11. Retrieved 2023-11-30.
  56. ↑ Schmidt K, Kraft HG, Parson W, Utermann G (February 2006). "Genetics of the Lp(a)/apo(a) system in an autochthonous Black African population from the Gabon". European Journal of Human Genetics. 14 (2): 190–201. doi: 10.1038/sj.ejhg.5201512 . PMID   16267501.
  57. ↑ Dahlén GH, Ekstedt B (September 2001). "The importance of the relation between lipoprotein(a) and lipids for development of atherosclerosis and cardiovascular disease". Journal of Internal Medicine. 250 (3): 265–267. doi: 10.1046/j.1365-2796.2001.00889.x . PMID   11555135. S2CID   44679184.
  58. ↑ Dumitrescu L, Glenn K, Brown-Gentry K, Shephard C, Wong M, Rieder MJ, et al. (January 2011). Kloss-Brandstaetter A (ed.). "Variation in LPA is associated with Lp(a) levels in three populations from the Third National Health and Nutrition Examination Survey". PLOS ONE. 6 (1): e16604. Bibcode:2011PLoSO...616604D. doi: 10.1371/journal.pone.0016604 . PMC   3030597 . PMID   21305047.{{cite journal}}: CS1 maint: overridden setting (link)
  59. ↑ Virani SS, Brautbar A, Davis BC, Nambi V, Hoogeveen RC, Sharrett AR, et al. (January 2012). "Associations between lipoprotein(a) levels and cardiovascular outcomes in black and white subjects: the Atherosclerosis Risk in Communities (ARIC) Study". Circulation. 125 (2): 241–249. doi:10.1161/CIRCULATIONAHA.111.045120. PMC   3760720 . PMID   22128224.{{cite journal}}: CS1 maint: overridden setting (link)
  60. ↑ Marcovina SM, Albers JJ, Scanu AM, Kennedy H, Giaculli F, Berg K, et al. (December 2000). "Use of a reference material proposed by the International Federation of Clinical Chemistry and Laboratory Medicine to evaluate analytical methods for the determination of plasma lipoprotein(a)". Clinical Chemistry. 46 (12): 1956–1967. doi: 10.1093/clinchem/46.12.1956 . PMID   11106328.{{cite journal}}: CS1 maint: overridden setting (link)
  61. ↑ Dati F, Tate JR, Marcovina SM, Steinmetz A (2004). "First WHO/IFCC International Reference Reagent for Lipoprotein(a) for Immunoassay--Lp(a) SRM 2B". Clinical Chemistry and Laboratory Medicine. 42 (6): 670–676. doi:10.1515/CCLM.2004.114. PMID   15259385. S2CID   24696473.
  62. ↑ Ryan, George M, Julius Torelli (2005). Beyond cholesterol: 7 life-saving heart disease tests that your doctor may not give you. New York: St. Martin's Griffin. p.  91. ISBN   978-0-312-34863-2.
  63. ↑ Boerwinkle E, Menzel HJ, Kraft HG, Utermann G (April 1989). "Genetics of the quantitative Lp(a) lipoprotein trait. III. Contribution of Lp(a) glycoprotein phenotypes to normal lipid variation". Human Genetics. 82 (1): 73–78. doi:10.1007/BF00288277. PMID   2523852. S2CID   912295.
  64. ↑ "FDA Grants Breakthrough Device Designation to Blood Test Measuring Lp(a)". HCP Live. 2024-05-22. Archived from the original on 2024-05-26. Retrieved 2024-06-11.
  65. ↑ Boden WE, Sidhu MS, Toth PP (March 2014). "The therapeutic role of niacin in dyslipidemia management". Journal of Cardiovascular Pharmacology and Therapeutics. 19 (2): 141–158. doi:10.1177/1074248413514481. PMID   24363242. S2CID   5134822.
  66. ↑ Sahebkar A, Katsiki N, Ward N, Reiner Ž (May 2021). "Flaxseed Supplementation Reduces Plasma Lipoprotein(a) Levels: A Meta-Analysis". Alternative Therapies in Health and Medicine. 27 (3): 50–53. PMID   31634874.
  67. ↑ Zmunda JM, Thompson PD, Dickenson R, Bausserman LL (June 1996). "Testosterone decreases lipoprotein(a) in men". The American Journal of Cardiology. 77 (14): 1244–1247. doi: 10.1016/S0002-9149(96)00174-9 . PMID   8651107.
  68. ↑ Zmunda JM, Thompson PD, Dickenson R, Bausserman LL (June 1996). "Testosterone decreases lipoprotein(a) in men". The American Journal of Cardiology. 77 (14): 1244–1247. doi: 10.1016/S0002-9149(96)00174-9 . PMID   8651107.
  69. ↑ Parhofer KG (2011). "Lipoprotein(a): medical treatment options for an elusive molecule". Current Pharmaceutical Design. 17 (9): 871–876. doi:10.2174/138161211795428777 (inactive 2024-04-11). PMID   21476974.{{cite journal}}: CS1 maint: DOI inactive as of April 2024 (link)
  70. ↑ Anagnostis P, Galanis P, Chatzistergiou V, Stevenson JC, Godsland IF, Lambrinoudaki I, et al. (May 2017). "The effect of hormone replacement therapy and tibolone on lipoprotein (a) concentrations in postmenopausal women: A systematic review and meta-analysis". Maturitas. 99: 27–36. doi:10.1016/j.maturitas.2017.02.009. hdl: 10044/1/48763 . PMID   28364865.{{cite journal}}: CS1 maint: overridden setting (link)
  71. ↑ Sahebkar A, Serban MC, Penson P, Gurban C, Ursoniu S, Toth PP, et al. (July 2017). "The Effects of Tamoxifen on Plasma Lipoprotein(a) Concentrations: Systematic Review and Meta-Analysis". Drugs. 77 (11): 1187–1197. doi:10.1007/s40265-017-0767-4. PMC   5501893 . PMID   28573436.{{cite journal}}: CS1 maint: overridden setting (link)
  72. ↑ Serban MC, Sahebkar A, Mikhailidis DP, Toth PP, Jones SR, Muntner P, et al. (January 2016). "Impact of L-carnitine on plasma lipoprotein(a) concentrations: A systematic review and meta-analysis of randomized controlled trials". Scientific Reports. 6: 19188. Bibcode:2016NatSR...619188S. doi:10.1038/srep19188. PMC   4709689 . PMID   26754058.{{cite journal}}: CS1 maint: overridden setting (link)
  73. ↑ Parhofer KG (2011). "Lipoprotein(a): medical treatment options for an elusive molecule". Current Pharmaceutical Design. 17 (9): 871–876. doi:10.2174/138161211795428777 (inactive 2024-04-11). PMID   21476974.{{cite journal}}: CS1 maint: DOI inactive as of April 2024 (link)
  74. ↑ Kim KA, Park HJ (January 2023). "New Therapeutic Approaches to the Treatment of Dyslipidemia 2: LDL-C and Lp(a)". Journal of Lipid and Atherosclerosis. 12 (1): 37–46. doi:10.12997/jla.2023.12.1.37. PMC   9884549 . PMID   36761062.
  75. ↑ "Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report". Pediatrics. 128 Suppl 5 (Suppl 5): S213–S256. December 2011. doi:10.1542/peds.2009-2107C. PMC   4536582 . PMID   22084329.
  76. ↑ Bonen DK, Nassir F, Hausman AM, Davidson NO (August 1998). "Inhibition of N-linked glycosylation results in retention of intracellular apo[a] in hepatoma cells, although nonglycosylated and immature forms of apolipoprotein[a] are competent to associate with apolipoprotein B-100 in vitro". Journal of Lipid Research. 39 (8): 1629–1640. doi: 10.1016/S0022-2275(20)32192-1 . PMID   9717723.
  77. ↑ Nassir F, Xie Y, Davidson NO (April 2003). "Apolipoprotein[a] secretion from hepatoma cells is regulated in a size-dependent manner by alterations in disulfide bond formation". Journal of Lipid Research. 44 (4): 816–827. doi: 10.1194/jlr.M200451-JLR200 . PMID   12562843.
  78. ↑ Klose R, Fresser F, Kochl S, Parson W, Kapetanopoulos A, Fruchart-Najib J, et al. (December 2000). "Mapping of a minimal apolipoprotein(a) interaction motif conserved in fibrin(ogen) beta - and gamma -chains". The Journal of Biological Chemistry. 275 (49): 38206–38212. doi: 10.1074/jbc.M003640200 . PMID   10980194.{{cite journal}}: CS1 maint: overridden setting (link)
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.